Reimbursement & Access
Whether payers — public programs and private insurers — will pay for an approved device and its ongoing support, and whether patients can actually obtain it: the economic gate that determines real-world availability after regulatory approval. Approval establishes that a device may be sold; reimbursement determines whether it will be used. The two are separate hurdles with different evidence demands, because payers weigh cost-effectiveness and comparative benefit, not merely safety and efficacy.
BCIs are costly — surgery, hardware, and continuing technical and clinical support — and coverage decisions, billing codes, and payment levels typically lag approval by years. Access further depends on infrastructure: specialist centers, trained clinicians, and durable long-term maintenance. Even a reimbursed device may therefore reach only a fraction of eligible patients, compounding the equity concerns already introduced by narrow selection criteria.
Even after approval, a BCI needs a billing code, a payer coverage decision, and a payment level before a hospital can offer it without absorbing the loss. History with other implants shows this can take years, during which an approved device is effectively unavailable outside a few academic centers.
Coverage, coding, and payment are three further gates that stand between approval and a patient actually receiving the device.
Approval without reimbursement is a common reason a technically successful device never reaches patients; regulatory success and market access are not the same milestone.